LYMPHOID NEOPLASIA PLCG 1 mutations in cutaneous T-cell lymphomas

PLCG1 mutations in cutaneous T-cell lymphomas José P. Vaqué, Gonzalo Gómez-López, Verónica Monsálvez, Ignacio Varela, Nerea Martı́nez, Cristina Pérez, Orlando Domı́nguez, Osvaldo Graña, José L. Rodrı́guez-Peralto, Socorro M. Rodrı́guez-Pinilla, Carmen González-Vela, Miriam Rubio-Camarillo, Esperanza Martı́n-Sánchez, David G. Pisano, Evangelia Papadavid, Theodora Papadaki, Luis Requena, José A. Garcı́a-Marco, Miriam Méndez, Mariano Provencio, Mercedes Hospital, Dolores Suárez-Massa, Concepción Postigo, David San Segundo, Marcos López-Hoyos, Pablo L. Ortiz-Romero, Miguel A. Piris, and Margarita Sánchez-Beato

[1]  Alfonso Valencia,et al.  RUbioSeq: a suite of parallelized pipelines to automate exome variation and bisulfite-seq analyses , 2013, Bioinform..

[2]  D. Hwang,et al.  Phospholipase signalling networks in cancer , 2012, Nature Reviews Cancer.

[3]  L. Staudt,et al.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics , 2012, Nature.

[4]  W. Marasco,et al.  Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells , 2012, Molecular Cancer Therapeutics.

[5]  C. Assaf,et al.  The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome , 2012, The British journal of dermatology.

[6]  D. Pisano,et al.  New Mutations in Chronic Lymphocytic Leukemia Identified by Target Enrichment and Deep Sequencing , 2012, PloS one.

[7]  R. Clark,et al.  Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. , 2012, Blood.

[8]  C. Geisler,et al.  Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome , 2012, Leukemia.

[9]  M. Wasik,et al.  The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma , 2011, Cancer biology & therapy.

[10]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[11]  E. Giné,et al.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.

[12]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[13]  P. Porcu,et al.  Evolving Insights in the Pathogenesis and Therapy of Cutaneous T‐cell lymphoma (Mycosis Fungoides and Sezary Syndrome) , 2011, British journal of haematology.

[14]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[15]  C. Geisler,et al.  Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. , 2011, The Journal of investigative dermatology.

[16]  G. Przybylski,et al.  Genetic alterations in Sezary syndrome , 2011, Leukemia & lymphoma.

[17]  B. Gorentla,et al.  Receptor signaling in immune cell development and function , 2011, Immunologic research.

[18]  C. Klemke,et al.  High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. , 2011, Blood.

[19]  Joseph M. Connors,et al.  Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.

[20]  J. Scarisbrick,et al.  Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Mark S. Sundrud,et al.  Synergistic and combinatorial control of T cell activation and differentiation by transcription factors. , 2010, Current opinion in immunology.

[22]  V. Romagosa,et al.  Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. , 2010, The Journal of investigative dermatology.

[23]  P. Fadda,et al.  Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays. , 2009, Cancer research.

[24]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[25]  S. Devesa,et al.  Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. , 2009, Blood.

[26]  Xuesong Wu,et al.  Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. , 2009, The Journal of investigative dermatology.

[27]  Chieh-Shan Wu,et al.  Differential CCR4 Expression And Function in Cutaneous T‐Cell Lymphoma Cell Lines , 2008, The Kaohsiung journal of medical sciences.

[28]  Amy E. Hawkins,et al.  DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.

[29]  C. Paweletz,et al.  Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. , 2008, Cancer research.

[30]  Remco Dijkman,et al.  Novel and highly recurrent chromosomal alterations in Sézary syndrome. , 2008, Cancer research.

[31]  E. Rallis,et al.  Successful treatment of patch type mycosis fungoides with tacrolimus ointment 0.1%. , 2006, Journal of drugs in dermatology : JDD.

[32]  S. Tuomela,et al.  Th1 Response and Cytotoxicity Genes Are Down-Regulated in Cutaneous T-Cell Lymphoma , 2006, Clinical Cancer Research.

[33]  F. Macian,et al.  NFAT proteins: key regulators of T-cell development and function , 2005, Nature Reviews Immunology.

[34]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[35]  Jennifer Trinh,et al.  Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. , 2005, Blood.

[36]  E. Tartour,et al.  Expression and activity of IL‐17 in cutaneous T‐cell lymphomas (mycosis fungoides and sezary syndrome) , 2004, International journal of cancer.

[37]  S. Whittaker,et al.  Molecular cytogenetic characterization of Sézary syndrome , 2003, Genes, Chromosomes and Cancer.

[38]  G. Pinkus,et al.  Increased CCR4 expression in cutaneous T cell lymphoma. , 2002, The Journal of investigative dermatology.

[39]  A. Dopazo,et al.  Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. , 2002, The American journal of pathology.

[40]  B. Czepulkowski,et al.  Molecular cytogenetic analysis of cutaneous T‐cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides , 2002, The British journal of dermatology.

[41]  Julia M. Lewis,et al.  Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. , 2012, The Journal of investigative dermatology.

[42]  M. Wasik,et al.  Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. , 2008, Journal of immunology.

[43]  S. Watson,et al.  Regulation of phospholipase C gamma isoforms in haematopoietic cells: why one, not the other? , 2001, Cellular signalling.